Perimenopause vs menopause is not a comparison between two phases — it is a comparison between a multi-year transition and a single retrospective moment in time. Perimenopause is the menopausal transition, a span of fluctuating hormones and irregular cycles that typically lasts four to eight years. Menopause, by contrast, is one day: the date marking twelve consecutive months without a menstrual period, identified only in hindsight. Everything after that day is post-menopause. The distinction matters because it shapes how clinicians diagnose, when pregnancy is still possible, and whether the evidence base on hormone therapy applies.
In this article
- The simple definition that gets the language right
- The STRAW+10 staging framework — all seven stages
- How FSH, estradiol, progesterone, and AMH behave across each stage
- Why menopause is diagnosed retrospectively, not in real time
- The "timing hypothesis" and what the WHI re-analysis showed
- Pregnancy risk during and after the transition
- When the peri-versus-post distinction changes clinical decisions
The simple definition: peri is the transition, menopause is one moment in time
The clearest way to separate the two terms is this: perimenopause describes the years of reproductive aging during which the ovaries lose follicular reserve and cycles become irregular; menopause is the date of the final menstrual period (FMP), confirmed only after twelve months of amenorrhea have passed. The interval after that date is post-menopause. The phrase "going through menopause" — while culturally universal — refers almost always to perimenopause, not menopause itself.
According to the Menopause Society (NAMS), the average age of the final menstrual period in the United States is 51 to 52, with a normal range from 45 to 55. Perimenopause may begin in the late 30s and typically lasts four to eight years before the FMP. Premature menopause refers to an FMP before age 40; early menopause refers to an FMP between 40 and 45.
This terminology is not pedantic. Insurance coding, clinical trial eligibility, contraceptive guidance, and hormone therapy risk-benefit calculations all hinge on which side of the FMP a patient sits.
The STRAW+10 staging framework — all seven stages explained
The Stages of Reproductive Aging Workshop +10 (STRAW+10) framework, published in 2012, is the international standard for staging female reproductive aging. It identifies seven stages with the final menstrual period as Stage 0, and is endorsed by NAMS, the International Menopause Society, the Endocrine Society, and the American Society for Reproductive Medicine.
| Stage | Name | Typical age range | Defining features |
|---|---|---|---|
| −3 | Late reproductive | Late 30s to mid-40s | Subtle changes in cycle length or flow; declining AMH and antral follicle count; FSH variable but rising on early follicular days |
| −2 | Early menopausal transition (early peri) | Mid- to late 40s | Persistent cycle-length variability of ≥7 days between consecutive cycles; FSH variable and elevated |
| −1 | Late menopausal transition (late peri) | Late 40s to early 50s | One or more intervals of amenorrhea ≥60 days; vasomotor symptoms most likely; FSH often >25 IU/L |
| 0 | Final menstrual period (FMP) | Average 51–52 | The last menstrual bleed — identified only retrospectively after 12 months of amenorrhea |
| +1a | Early post-menopause (first year) | FMP + 0–1 year | Completion of the 12-month amenorrhea interval; FSH continues to rise; estradiol continues to fall |
| +1b | Early post-menopause (years 2–6) | FMP + 1–6 years | Vasomotor symptoms remain common; FSH and estradiol stabilize at post-menopausal values |
| +1c / +2 | Late post-menopause | FMP + 6+ years | Genitourinary syndrome of menopause becomes more prevalent; somatic aging predominates over reproductive aging |
STRAW+10 explicitly notes that single-day blood tests cannot stage perimenopause accurately — menstrual pattern is the primary criterion, with hormone testing as a supportive marker (Harlow et al., 2012).
Hormone behaviour at each stage
Most online summaries describe perimenopause as "declining estrogen." The reality is more chaotic. Estradiol fluctuates widely — sometimes higher than reproductive baseline — before falling. FSH rises but is highly variable cycle to cycle. Progesterone declines earliest, owing to a rising rate of anovulatory cycles. Anti-Müllerian hormone (AMH), a marker of remaining follicle pool, falls steadily from the late reproductive stage onward. The Study of Women's Health Across the Nation (SWAN) longitudinal cohort is the largest dataset describing these trajectories.
| Hormone | Late reproductive (Stage −3) | Perimenopause (Stages −2/−1) | Early post-menopause (+1a/+1b) | Late post-menopause (+1c/+2) |
|---|---|---|---|---|
| FSH | Normal early-follicular range; subtle rise on cycle day 3 | Variable and rising; spikes followed by drops | Persistently elevated, typically >25 IU/L | Stably elevated |
| Estradiol (E2) | Mostly normal; occasional high readings | Highly fluctuating; can be higher OR lower than reproductive baseline | Low and stabilizing | Persistently low |
| Progesterone | Begins to decline as anovulatory cycles appear | Frequently low due to anovulation | Negligible from ovarian source | Negligible |
| AMH | Declining | Low | Often undetectable | Undetectable |
The Endocrine Society clinical practice guidelines caution against diagnosing perimenopause from a single hormone panel. Menstrual history, age, and symptom pattern are the primary criteria; labs corroborate.
How menopause is actually diagnosed: the 12-month rule
Menopause is a retrospective diagnosis. The Menopause Society and STRAW+10 define it as the point twelve consecutive months after the final menstrual period, in the absence of another cause. There is no blood test, ultrasound, or symptom checklist that can declare a menstruating woman menopausal in real time.
Several practical implications follow:
- A woman who has not bled in eleven months is still in late perimenopause (Stage −1), not menopause.
- Hormonal contraception, hysterectomy with ovarian preservation, endometrial ablation, and the levonorgestrel IUD all obscure menstrual cues. In these cases clinicians rely on symptom pattern plus selective FSH testing, recognizing the limits of any single value.
- Bleeding twelve or more months after the apparent FMP is post-menopausal bleeding and is evaluated per ACOG guidance, given the elevated risk of endometrial malignancy.
Why the "timing hypothesis" matters for hormone therapy decisions
The most consequential reason to distinguish peri, early post-menopause, and late post-menopause is that the evidence base on menopausal hormone therapy (MHT) is age- and time-dependent. The original Women's Health Initiative (WHI) trials, published in the early 2000s, reported increased cardiovascular and breast cancer risks with combined hormone therapy. Subsequent stratified analyses showed those risk estimates were driven largely by women in their 60s and 70s starting therapy a decade or more after menopause.
In 2017, Manson and colleagues published an 18-year follow-up of the WHI cohorts in JAMA. The pooled analysis found no significant increase in all-cause, cardiovascular, or cancer mortality among women randomized to hormone therapy, and signals of reduced all-cause mortality in women who initiated therapy before age 60 or within ten years of menopause onset. The Menopause Society's 2022 position statement now formally endorses this "timing hypothesis" or "window of opportunity": the benefit-risk profile of MHT is most favourable when initiated in symptomatic women under 60 or within ten years of the FMP, in the absence of contraindications.
This is evidence to discuss, not a prescription. Personal and family history of breast cancer, thromboembolic disease, cardiovascular disease, migraine with aura, and individual symptom burden all weigh into the calculation. Patients considering hormone therapy may benefit from discussing the timing-hypothesis evidence with their prescribing physician, who can interpret the data against their personal risk profile.
Can you still get pregnant during perimenopause? And after?
Yes — perimenopause is not a contraceptive state. Ovulation becomes irregular but does not stop until the final menstrual period, and a woman cannot know in real time that any given cycle is her last. ACOG and NAMS guidance state that pregnancy remains possible throughout perimenopause and that contraception should be continued until either twelve consecutive months of amenorrhea in women over 50, or twenty-four consecutive months in women under 50, given the higher likelihood of sporadic ovulation in the younger group.
After the 12-month threshold, spontaneous pregnancy is no longer considered a clinical possibility, and any bleeding from that point forward is evaluated as post-menopausal bleeding. Sexually transmitted infection risk does not decline with reproductive aging, so barrier methods remain appropriate regardless of pregnancy potential.
When the distinction matters for clinical decisions
Several clinical pivots hinge on whether a patient is in late perimenopause, early post-menopause, or late post-menopause:
- Contraceptive counselling. Continue contraception in perimenopause; reassess at the 12-month amenorrhea threshold.
- Evaluation of abnormal bleeding. Heavy or irregular bleeding in late perimenopause warrants endometrial assessment per ACOG. Any bleeding after the 12-month threshold is post-menopausal bleeding until proven otherwise.
- Hormone therapy candidacy. The timing hypothesis applies; risk-benefit shifts with years since FMP.
- Bone health screening. DXA screening is recommended in post-menopausal women according to the USPSTF, with timing influenced by post-menopausal status and risk factors.
- Cardiovascular risk stratification. Risk increases after menopause; lipid and blood pressure surveillance follows accordingly.
- Genitourinary syndrome of menopause. More prevalent in late post-menopause; clinical approach differs from vasomotor symptoms of early transition.
What functional medicine practitioners look for
A functional medicine evaluation of a woman at any STRAW+10 stage typically extends beyond the conventional menopause workup. Common areas of assessment include:
- Cycle pattern history over the prior 24 months, mapped to STRAW+10 stage
- Symptom inventory — vasomotor, sleep, mood, cognitive, genitourinary, musculoskeletal
- Hormone panel interpreted in the context of cycle timing and STRAW+10 stage, recognizing single-value limitations
- Thyroid function, which often mimics or amplifies perimenopausal symptoms
- Metabolic markers — fasting insulin, HbA1c, lipids — given the increased cardiometabolic risk at and after the transition
- Inflammatory and micronutrient markers as supported by published literature
- Bone health baseline and risk factors
- Family history of breast cancer, cardiovascular disease, thromboembolism, and osteoporosis to inform any future hormone therapy discussion
This is framework-level information. Specific testing, interpretation, and any treatment decisions belong to the clinical encounter and to the prescribing clinician.
When to consider booking a consult
A deeper workup may be warranted if a patient identifies with several of the following:
- Cycles have become noticeably irregular or heavier, and standard evaluation has not clarified the cause
- Vasomotor symptoms, sleep disruption, or mood change are interfering with daily function
- There is uncertainty about STRAW+10 stage or whether menopause has been reached
- A hormone therapy decision is being considered and the patient wants to understand the timing-hypothesis evidence before discussing it with a prescribing clinician
- Cycles stopped before age 45, suggesting early menopause
- Symptoms persist years into post-menopause and have not been addressed
- Bone, cardiometabolic, or cognitive concerns have emerged around the transition
Frequently asked questions
Is perimenopause the same as menopause?
No. Perimenopause is the multi-year menopausal transition, characterized by fluctuating hormones and increasingly irregular cycles. Menopause is the single day of the final menstrual period, identified retrospectively after twelve consecutive months without a period. Everything after that day is post-menopause. The cultural use of the word "menopause" to mean "the change" is imprecise — most symptomatic women are technically in perimenopause, not menopause itself. The distinction matters for diagnosis, contraception decisions, and how the evidence on hormone therapy is applied (NAMS, 2022).
How is menopause diagnosed?
Menopause is diagnosed retrospectively, twelve consecutive months after the final menstrual period in the absence of another cause. There is no real-time blood test that can confirm a menstruating woman is menopausal. FSH and estradiol levels can support staging but are highly variable in perimenopause and should not be used in isolation. In patients on hormonal contraception, after hysterectomy with ovarian preservation, or after endometrial ablation, clinicians rely on symptom pattern and selective lab testing because menstrual cues are unavailable (STRAW+10 framework, Harlow et al., 2012).
Can a woman still get pregnant during perimenopause?
Yes. Ovulation becomes irregular during perimenopause but does not stop until the final menstrual period — and that final period is only identifiable in hindsight. ACOG and the Menopause Society advise continuing contraception until twelve consecutive months of amenorrhea in women over 50, or twenty-four months in women under 50, because younger perimenopausal women have a higher chance of sporadic ovulation. Pregnancy is not considered a possibility after the 12-month amenorrhea threshold defines menopause.
What is the "timing hypothesis" for hormone therapy?
The timing hypothesis describes the observation that the risk-benefit profile of menopausal hormone therapy depends on the patient's age and years since menopause at initiation. The 18-year follow-up of the Women's Health Initiative (Manson et al., JAMA, 2017) found that women who initiated therapy before age 60 or within ten years of the final menstrual period had a more favourable mortality profile than those who initiated therapy later. Patients considering hormone therapy may benefit from discussing this evidence with their prescribing physician, who can weigh it against personal and family risk factors.
How long does perimenopause typically last?
Perimenopause typically lasts four to eight years before the final menstrual period, though the range across populations is wider. The Study of Women's Health Across the Nation (SWAN) longitudinal cohort has documented substantial variability tied to age at onset, ethnicity, smoking status, and parity. Early menopausal transition (Stage −2) can be subtle and lengthy; late menopausal transition (Stage −1) — defined by intervals of ≥60 days of amenorrhea — is usually shorter, often one to three years. Total transition duration is best characterized by following menstrual pattern over time rather than by any single test.
About the author
About the author
Anna Evans, MSN, APRN, FNP-C is a board-certified Family Nurse Practitioner licensed in Texas. She founded Interlinked Wellness, a virtual functional medicine practice serving women across Texas from offices in Dallas and Austin. Her clinical focus is perimenopause, hormone imbalance, gut health, thyroid and autoimmune conditions, and chronic fatigue.
For a broader treatment of the transition itself, see the complete guide to perimenopause for women.
Medical disclaimer
Medical disclaimer. This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, treatment, or a substitute for consultation with a qualified healthcare provider. Reading this article does not establish a patient-provider relationship with Interlinked Wellness or Anna Evans, MSN, APRN, FNP-C. Always seek the advice of your physician, nurse practitioner, or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay seeking it because of something you have read on this site. If you think you may have a medical emergency, call 911 or your local emergency services immediately.
Join Anna on a virtual wellness journey and unlock your full potential.
